The 3-phase evolution of stored red blood cells and the clinical trials: An obvious relationship

Blood Transfusion

Volumn 15, Issue 2, 2017, Pages 188-

  Prudent, Michel ^a   Tissot, Jean Daniel ^a   Lion, Niels ^a  

^a laboratoire de recherche sur les produits sanguins   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; CLINICAL TRIAL (TOPIC); ERYTHROCYTE CONCENTRATE; ERYTHROCYTE PRESERVATION; ERYTHROCYTE TRANSFUSION; HUMAN; LETTER; MORBIDITY; MORTALITY; BLOOD STORAGE; CYTOLOGY; ERYTHROCYTE; ERYTHROCYTE LIFESPAN; METABOLISM; PROCEDURES;

BLOOD PRESERVATION; CLINICAL TRIALS AS TOPIC; ERYTHROCYTE AGING; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; HUMANS;

EID: 85016048911     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2017.0317-16     Document Type: Letter

References (5)

1. Heddle NM, Cook RJ, Arnold DM, et al. Effect of short-term vs. long-term blood storage on mortality after transfusion. New Engl J Med 2016; 375: 1937-45.
2. Glynn SA, Klein HG, Ness PM. The red blood cell storage lesion: the end of the beginning. Transfusion 2016; 56: 1462-8.
3. Prudent M, Tissot JD, Lion N. In vitro assays and clinical trials in red blood cell aging: lost in translation. Transfus Apher Sci 2015; 52: 270-6.
4. Paglia G, D'Alessandro A, Rolfsson O, et al. Biomarkers defining the metabolic age of red blood cells during cold storage. Blood 2016; 128: E43-50.
5. Goel R, Johnson DJ, Scott AV, et al. Red blood cells stored 35 days or more are associated with adverse outcomes in high-risk patients. Transfusion 2016; 56: 1690-8.